377 related articles for article (PubMed ID: 34268808)
1. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
[TBL] [Abstract][Full Text] [Related]
2. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
3. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
4. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
Zheng M; Li Y; Li T; Zhang L; Zhou L
Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
[TBL] [Abstract][Full Text] [Related]
6. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
7. An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm.
Liu H; Xie R; Zhao Z; Xu D; Yang K; Ding M; Tan D; Liao W; Han X; Zhang J; Shen D; Yuan J; Xu Z; Fei J
Medicine (Baltimore); 2020 Aug; 99(33):e21682. PubMed ID: 32872039
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological characterization of gastro-entero- pancreatic neuroendocrine tumors].
Borka K
Magy Onkol; 2018 Jul; 62(2):90-97. PubMed ID: 30027936
[TBL] [Abstract][Full Text] [Related]
9. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
[TBL] [Abstract][Full Text] [Related]
10. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
[TBL] [Abstract][Full Text] [Related]
11. Lung Metastases in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms: An Appraisal of the Validity of Thoracic Imaging Surveillance.
Daskalakis K; Tsoli M; Srirajaskanthan R; Chatzellis E; Alexandraki K; Angelousi A; Pizanias M; Randeva H; Kaltsas G; Weickert MO
Neuroendocrinology; 2019; 108(4):308-316. PubMed ID: 30673674
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
13. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
[TBL] [Abstract][Full Text] [Related]
14. Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors.
Gonzalez RS; Cates JMM; Shi C
Mod Pathol; 2018 Oct; 31(10):1560-1566. PubMed ID: 29795438
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
[TBL] [Abstract][Full Text] [Related]
16. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
17. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
Baptiste GG; Postlewait LM; Ethun CG; Le N; McInnis MR; Russell MC; Winer JH; Kooby DA; Staley CA; Maithel SK; Cardona K
J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
20. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]